TAIPEI, TAIWAN--(Marketwired - Mar 30, 2016) - BioBusiness Asia 2016 (BBA) will feature a session on Biotherapeutics, hosted by the National Research Program for Biopharmaceuticals (NRPB, Taiwan). In today's competitive world of biological development and the ever increasing regulatory demands, Session III and Session IV will explore approaches and business models in moving forward the immunotherapy research and commercialization in Taiwan and the ASEAN region.

Hear perspectives from multinational company business development leaders speak on immunotherapy and cell therapy paradigm, business models from technology to industry and top CRO speakers exploring clinical development strategies for leading product candidates at Session III titled New Advancements in Biotherapeutics. Session IV will focus on Commercialization of Novel Biotherapeutics, strategies on building successful business model and valuating technology/company transaction and maximizing biotherapeutics value through IP strategies with speakers from Fraunhofer's Head of Business Development and Patent Management, Venture Valuation CEO and more.

We anticipate more than 200 registering for this event, where business executives and community leaders gather at the CTBC Financial Hall, Taipei, to hear successful business models and commercialization process to enhance and empower the industry and academics in Taiwan.

About Development Center for Biotechnology, Taiwan
DCB is a not-for-profit research organization, founded in 1984 and supported by government funding and private donations. DCB's objective is to advance Taiwan's biotech-pharma industry by building infrastructure, developing key technologies, and train talented workforces in coordination with government, industry, and academic institutions. DCB positions itself as a "Preclinical Value-Adding R&D Center for Biopharmaceuticals". This role is to be fulfilled by devoting concerted R&D efforts on protein, small molecule and botanical drug leads in the preclinical stage of development and setting top priorities for attaining Investigational New Drug approvals by domestic and foreign regulatory agencies. Please see website for more details at

Contact Information:

Press contact:
Daisy Tsai